Stockscreener 앱 받기
762.49
1.15%
-9.22
시간 외 거래:
763.05
0.56
+0.07%
전일 마감가:
$771.71
열려 있는:
$768.17
하루 거래량:
2.53M
Relative Volume:
0.66
시가총액:
$722.80B
수익:
$49.00B
순이익/손실:
$11.11B
주가수익비율:
62.04
EPS:
12.29
순현금흐름:
$-1.27B
1주 성능:
-4.56%
1개월 성능:
+0.02%
6개월 성능:
+2.76%
1년 성능:
-11.03%
1일 변동 폭
$760.50
$772.00
1주일 범위
$760.02
$805.42
52주 변동 폭
$677.09
$972.53
일라이 릴리 Stock (LLY) Company Profile
명칭
Lilly Eli Co
전화
(317) 276-2000
주소
LILLY CORPORATE CTR, INDIANAPOLIS, IN
LLY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
762.66 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.40 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.89 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.18 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.94 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
일라이 릴리 Stock (LLY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-04-28 | 다운그레이드 | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-09-13 | 재개 | Citigroup | Buy |
| 2024-08-12 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-02-21 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2024-02-16 | 재확인 | Morgan Stanley | Overweight |
| 2023-12-21 | 다운그레이드 | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-20 | 재개 | UBS | Buy |
| 2023-08-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-26 | 재확인 | Citigroup | Buy |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-05-24 | 재확인 | BofA Securities | Buy |
| 2023-05-24 | 재확인 | UBS | Buy |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-15 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-09-22 | 업그레이드 | UBS | Neutral → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-03-10 | 개시 | Daiwa Securities | Outperform |
| 2022-01-21 | 업그레이드 | DZ Bank | Hold → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-16 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-16 | 재확인 | BofA Securities | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-10-11 | 업그레이드 | Berenberg | Hold → Buy |
| 2021-09-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-05 | 업그레이드 | DZ Bank | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-06-24 | 재확인 | Cantor Fitzgerald | Overweight |
| 2021-01-19 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-12-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-09-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2019-12-18 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-04-24 | 업그레이드 | Edward Jones | Hold → Buy |
| 2019-04-11 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-03-12 | 개시 | JP Morgan | Overweight |
| 2019-01-23 | 개시 | UBS | Buy |
| 2018-11-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-10-31 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 개시 | Guggenheim | Buy |
| 2018-10-01 | 재확인 | SunTrust | Buy |
| 2018-09-26 | 재개 | JP Morgan | Overweight |
모두보기
일라이 릴리 주식(LLY)의 최신 뉴스
Eli Lilly’s Strategic Advantage in GLP-1RAs and Alzheimer’s Markets Fuels Buy Rating - TipRanks
Eli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade - The Motley Fool
Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT - Insider Monkey
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com
Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025 - Insider Monkey
J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating - Insider Monkey
Eli Lilly and Company - Lifespan Research Institute
Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily
Eli Lilly’s Innovative Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks
Eli Lilly’s New Study on LY4050784: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s LUCENT 3 Study: A Promising Step for Ulcerative Colitis Treatment - TipRanks
Eli Lilly’s KRAS Inhibitor Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Eli Lilly’s Lepodisiran Study: A Step Forward in Liver Function Treatment - TipRanks
Eli Lilly’s Weight Management Study: A Potential Game-Changer in Obesity Treatment - TipRanks
Eli Lilly’s Promising Phase 1 Study on LY4101174: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s New Cancer Study: A Potential Game-Changer? - TipRanks
Eli Lilly & Co: Analyst Bullish on Diabetes Segment and Oncology Franchise Amid Competitive Pressures. - AInvest
Eli Lilly & Co: Promising Growth Prospects and Strategic Positioning Amid Competitive Pressures - TipRanks
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? - The Motley Fool
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers By Investing.com - Investing.com India
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers - Investing.com
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today? - Yahoo Finance
Senators reveal how much Lilly, Pfizer paid telehealth companies - statnews.com
LLY Stock Quote Price and Forecast - CNN
Eli Lilly Bets Big On Obesity And Diabetes Drugs - Finimize
Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?” - MSN
ELI LILLY AND COMPANY (LLY) - MSN
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound - CNBC
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
Health Canada Expands Eli Lilly's Omvoh Indication to Crohn's, Approves Citrate-Free Formula - MarketScreener
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Eli Lilly’s Weight-Loss Drug Faces New Competition from China - TipRanks
Eli Lilly Foundation provides $5.5 million grant for STEM education initiative at IPS - Fox 59
The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises - Yahoo Finance
Eli Lilly: Still Too Pricey To Buy (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment - Insider Monkey
Eli Lilly (LLY) Gains Health Canada Approval for Omvoh in Crohn's Disease Treatment - GuruFocus
Eli Lilly’s Obesity Pill For The Masses Could Flip The $150 Billion Market on Its Head! - Smartkarma
Top Research Reports for Eli Lilly, Netflix & GE Aerospace - Yahoo Finance
Eli Lilly (LLY) Expects Results from Weight-Loss Pill Trial by Sept. 30 - TipRanks
Eli Lilly’s Weight Management Study: A Potential Game-Changer? - TipRanks
Eli Lilly’s New Study on SGLT2 Inhibitors: A Potential Game-Changer for CKD Anemia Management - TipRanks
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025) - 24/7 Wall St.
Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 20% Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into Indias Weigh-Loss Drug Sector - NDTV Profit
Eli Lilly and Company (LLY): I Would “Love” If Trump Praised The Company, Says Jim Cramer - Insider Monkey
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth - Yahoo Finance
Eli Lilly Surges Ahead: JPMorgan Sees $1,100 Price Target on Obesity Drug Boom - Yahoo
일라이 릴리 (LLY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
0.06%
자본화:
|
볼륨(24시간):